 |
|
Herceptin gives disappointing results in lung cancer trial
January 08, 2004Trastuzumab (Herceptin) - a treatment that has increased survival in many breast cancer patients - has failed to live up to hopes that it might also help lung cancer patients.
In a Phase II trial of over 100 patients with non-small-cell lung cancer (NSCLC) reported today (Tuesday 13 January) in Annals of Oncology[1], those treated with trastuzumab in combination with two chemotherapy agents gemcitabine and cisplatin, did no better than patients treated with gemcitabine and cisplatin alone.
There was a hint in the results that there could be a very small subgroup of lung cancer patients who may benefit. These are patients with extremely strong over-expression or amplification of HER2 - the gene that trastuzumab targets[2]. The international research team[3] believes that any future trials should focus on patients with high levels of HER2 over-expression or gene amplification. However, studies on those with the strongest possible over-expression or amplification will be difficult to carry out because the numbers of eligible patients will be small.
Lead researcher, Dr Ulrich Gatzemeier, Head of the Department of Thoracic Oncology, Zentrum für Pneumologie und Thoraxchirurgie, Krankenhaus Grosshansdorf, Germany, said that trastuzumab, combined with chemotherapy, had already shown major clinical benefit in women with HER2 positive breast cancer, including a significant increase in survival. As cell-line studies on HER2 positive NSCLC had shown that trastuzumab had an even greater synergy with gemcitabine and cisplatin than it had in breast cancer cells there was a rationale for believing that it might also benefit lung cancer patients.
"It was disappointing therefore to find that the survival times and the time to the disease progressing were very similar - between six and seven months for both the trastuzumab and control arms. However, we did find that the trastuzumab/chemotherapy combination was well tolerated and that five out of the six patients with extremely high levels of HER2 responded better than other HER2 patients. It was nearly eight and half months before their disease progressed compared with just over six months for the patients with less high HER2 levels. Unfortunately, this extremely high HER2 group made up less than two per cent of all the 619 patients we originally screened for trial eligibility and our data suggest that although nearly 60 per cent of NSCLC patients overall are HER2 positive any possible benefit of trastuzumab is likely to be confined to under five per cent of all patients with advanced NSCLC. That's only about 1,200 people per year in Germany. This makes future recruitment to clinical trials problematic and means that the likely clinical use of trastuzumab for NSCLC will be limited."
Dr Gatzemeier said that ongoing trials with other chemotherapy combinations might further define trastuzumab's potential use in NSCLC. But, it was important that any new trials focused on patients with high HER2 over-expression or amplification.
The main reason for the failure, according to Dr Gatzemeier, was that the majority of patients had lower levels (1+ and 2+) of high HER2 over-expression. Trastuzumab added nothing to an effective chemotherapy like cisplatin/gemcitabine - in accordance with other trials (INTACT, TALENT AND TRIBUTE) in which the aim was to inhibit receptors of epidermal growth factors. It was also possible that blocking only one of the growth factors was ineffective in NSCLC while there were parallel signalling pathways allowing the cancer to progress.
(ends)
[1]Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Annals of Oncology 15: 19-27.
[2]Trastuzumab (Herceptin) is a humanized monoclonal antibody rationally developed to target HER2 over-expressing cells. It has an additive or synergistic activity in combination with various cytotoxic chemotherapy in pre-clinical studies of breast cancer and NSCLC and is an effective new treatment in HER2 positive breast cancer.
[3]The trial involved an international team of researchers from Germany, Canada, the Netherlands, Italy and the UK, plus Roche Products Ltd., manufacturers of Herceptin.
MW Communications
Lead researcher, Dr Ulrich Gatzemeier, Head of the Department of Thoracic Oncology, Zentrum für Pneumologie und Thoraxchirurgie, Krankenhaus Grosshansdorf, Germany, said that trastuzumab, combined with chemotherapy, had already shown major clinical benefit in women with HER2 positive breast cancer, including a significant increase in survival. As cell-line studies on HER2 positive NSCLC had shown that trastuzumab had an even greater synergy with gemcitabine and cisplatin than it had in breast cancer cells there was a rationale for believing that it might also benefit lung cancer patients.
"It was disappointing therefore to find that the survival times and the time to the disease progressing were very similar - between six and seven months for both the trastuzumab and control arms. However, we did find that the trastuzumab/chemotherapy combination was well tolerated and that five out of the six patients with extremely high levels of HER2 responded better than other HER2 patients. It was nearly eight and half months before their disease progressed compared with just over six months for the patients with less high HER2 levels. Unfortunately, this extremely high HER2 group made up less than two per cent of all the 619 patients we originally screened for trial eligibility and our data suggest that although nearly 60 per cent of NSCLC patients overall are HER2 positive any possible benefit of trastuzumab is likely to be confined to under five per cent of all patients with advanced NSCLC. That's only about 1,200 people per year in Germany. This makes future recruitment to clinical trials problematic and means that the likely clinical use of trastuzumab for NSCLC will be limited."
Dr Gatzemeier said that ongoing trials with other chemotherapy combinations might further define trastuzumab's potential use in NSCLC. But, it was important that any new trials focused on patients with high HER2 over-expression or amplification.
The main reason for the failure, according to Dr Gatzemeier, was that the majority of patients had lower levels (1+ and 2+) of high HER2 over-expression. Trastuzumab added nothing to an effective chemotherapy like cisplatin/gemcitabine - in accordance with other trials (INTACT, TALENT AND TRIBUTE) in which the aim was to inhibit receptors of epidermal growth factors. It was also possible that blocking only one of the growth factors was ineffective in NSCLC while there were parallel signalling pathways allowing the cancer to progress.
(ends)
[1]Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Annals of Oncology 15: 19-27.
[2]Trastuzumab (Herceptin) is a humanized monoclonal antibody rationally developed to target HER2 over-expressing cells. It has an additive or synergistic activity in combination with various cytotoxic chemotherapy in pre-clinical studies of breast cancer and NSCLC and is an effective new treatment in HER2 positive breast cancer.
[3]The trial involved an international team of researchers from Germany, Canada, the Netherlands, Italy and the UK, plus Roche Products Ltd., manufacturers of Herceptin.
MW Communications
Breast Cancer Current Events and Breast Cancer News RSSAngled gantry technique reduced breast radiation exposure by 50 percent
A novel angled gantry approach to coronary CT angiography reduced radiation exposure to the breast by more than 50%, according to Thomas Jefferson University researchers.
HER2 levels may aid in treatment selection for metastatic breast cancer
Findings published in the December 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit.
Drop in cancer deaths tied primarily to gains in behavior and screening
Improvements in behavior and screening have contributed greatly to the 13 percent decline in cancer mortality since 1990, with better cancer treatments playing a supporting role, according to new research from David Cutler of Harvard University.
New breast imaging technology targets hard-to-detect cancers
Breast-specific gamma imaging (BSGI) is effective in the detection of cancers not found on mammograms or by clinical exam, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Delays in Radiation Therapy Lead to Increased Breast Cancer Recurrence
A new analysis of the National Cancer Institute's cancer registry has found that as many as one in five older women experience delayed or incomplete radiation treatment following breast-conserving surgery, and that this suboptimal care can lead to worse outcomes.
New mammography technology effective in detecting breast cancer
A study has found that positron emission mammography (PEM), a new technique for imaging the breast, is not affected by either breast density or a woman's hormonal status, two factors that limit the effectiveness of standard mammography and MRI at detecting cancer.
New statistical model could help reduce breast-lesion biopsies
A new method of characterizing breast lesions found during an MRI exam could result in fewer biopsies of benign tumors with the benefits of reduced pain and expense for patients and providers, according to a paper that will be presented today (Sunday, Nov. 30) at the annual meeting of the Radiological Society of North America (RSNA).
Breast cancer treatment offers better outcome to women with implants
Women with early-stage breast cancer who have undergone breast augmentation may be treated successfully with a partial-breast radiation treatment called brachytherapy, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Study identifies double-balloon enteroscopy as cost-effective approach for obscure GI bleeding
A cost-effectiveness analysis conducted by researchers at Stanford University Hospital in Calif., shows that an initial double-balloon enteroscopy (DBE) is a cost-effective approach for patients with obscure gastrointestinal (GI) bleeding.
Study identifies causes of bone loss in breast cancer survivors
Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss.
More Breast Cancer Current Events and Breast Cancer News Articles
 | Breast Cancer Husband : How to Help Your Wife (and Yourself) during Diagnosis, Treatment and Beyond by Marc Silver A unique guide, like none other on the market-packed with medical information, practical tips, psychological insight, and coping strategies-to help men help the women they love through this trying time. When Marc Silver became a breast cancer husband three years ago, he learned firsthand how frightened and helpless the breast cancer husband feels. He searched in vain for a book that would give... |
 | Breast Cancer Survival Manual, Fourth Edition: A Step-by-Step Guide for the Woman With Newly Diagnosed Breast Cancer by John Link A completely updated edition of the definitive guide for patients with breast cancer The new fourth edition of The Breast Cancer Survival Manual provides essential updates on treatment and care, enhancing the basic information that has made this the most trusted guide for women diagnosed with breast cancer for the past decade. This edition includes the most current advice on • getting a second... |
 | The Breast Cancer Survivor's Fitness Plan (Harvard Medical School Guides) by Carolyn M. Kaelin, Francesca Coltrera, Josie Gardiner, Joy Prouty The only breast cancer recovery program designed by a Harvard doctor and survivor and approved by the American Council on Exercise (ACE). . Feel healthy again. Regain control of your life. . . Exciting new research reveals that regular exercise can reduce the chance of breast cancer recurrence and extend your life. Exercise can also help you recover energy, strength, and flexibility... |
 | Chicken Soup for the Breast Cancer Survivor's Soul: Stories to Inspire, Support and Heal (Chicken Soup for the Soul) by Jack Canfield, Mark Victor Hansen, Mary Olsen Kelly Your support group in a book, filled with boundless strength and profound hope - until the fight is won. Along with the shock, fear and loss many women face upon a breast cancer diagnosis comes unexpected strength, wisdom, and strong networks of sharing, support and healing. In Chicken Soup for the Breast Cancer Survivor's Soul, survivors and their family members talk openly about how difficult... |
 | Choices in Breast Cancer Treatment: Medical Specialists and Cancer Survivors Tell You What You Need to Know (A Johns Hopkins Press Health Book) A diagnosis of breast cancer can be overwhelming. The disease is frightening and the medical landscape confusing. In the wake of fear and confusion comes the need to make decisions about treatment. This book provides women with medically reliable and up-to-date information to help them with these decisions.Within these pages is a team of private consultants -- including surgeons, medical... |
 | I Am Not My Breast Cancer: Women Talk Openly About Love and Sex, Hair Loss and Weight Gain, Mothers and Daughters, and Being a Woman with Breast Cancer by Ruth Peltason I Am Not My Breast Cancer gathers the warm, loving, frank, and informed voices of more than eight hundred women—from every state in the nation and from continents as far away as Australia and Africa—who reveal their fears, trade advice, share experiences, and express their deepest, most intimate concerns. Essential reading for any woman with this diagnosis, it offers the companionship of... |
 | The Breast Cancer Prevention Diet: The Powerful Foods, Supplements, and Drugs That Can Save Your Life by Dr. Bob Arnot "From one of the most visible and highly respected figures in medical journalism comes a book that can literally save lives. During the past several years, doctors at leading institutions across the nation have been investigating the relationship between breast cancer and diet. The recent flood of medical studies confirm that what a woman eats can have a dramatic impact on whether or not... |
 | Breast Cancer: Real Questions, Real Answers by David Chan Breast Cancer: Real Questions, Real Answers is an outgrowth of Dr. David Chan's more than 20 years in private oncology practice. Inspired by his patients—who courageously face their illness but often feel fearful, confused about their options, and full of questions—Dr. Chan's book is uniquely structured as a Question and Answer between patient and doctor. It provides readers with an easily... |
 | Breast Cancer? Breast Health! The Wise Woman Way (Wise Woman Herbal Series, Book 4) (Wise Woman Herbal Series) by Susun S. Weed Foods, exercises, and attitudes to keep your breasts healthy. Supportive complimentary medicines to ease side-effects of surgery, radiation, chemotherapy, or tamoxifen. Foreword by Christiane Northrup,... |
 | What Your Doctor May Not Tell You About(TM): Breast Cancer: How Hormone Balance Can Help Save Your Life (What Your Doctor May Not Tell You About...) by John R. Lee, David Zava, Virginia Hopkins An informative and absorbing read for both medical practitioners and their patients, What Your Doctor May Not Tell You About Breast Cancer takes aim at "the breast cancer industry" with a barrage of thought-provoking ammunition. The book is equal parts criticism and suggestion. Current health treatments, including HRT, receive serious condemnation, and authors John Lee and David Zava carefully... |
| © 2008 BrightSurf.com |